Physician profile
Stuart G Bark
NPI 1841302544
$3,841.20
in general payments reported to CMS, 2019-2025
13 companies · $32.65 in 2025
The $32.65 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,084 · 2020: $653 · 2021: $834 · 2022: $127 · 2023: $110 · 2025: $32.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110 · Entertainment: $32.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.25 |
| Entertainment | $32.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,145.73 | 2019-2023 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,079.83 | 2019-2021 | |
| Optovue, INC. | $281.38 | 2019 | |
| Alcon Vision LLC | $265.49 | 2019-2021 | |
| Maculogix, INC. | $245.23 | 2019-2020 | |
| Optos, INC. | $231.36 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Sight Sciences, INC. | $146.32 | 2019 | |
| Kala Pharmaceuticals, INC. | $118.17 | 2021 | |
| Alcon Research LLC | $117.51 | 2019 | |
| Sun Pharmaceutical Industries INC. | $95.59 | 2019 | |
| Glaukos Corporation | $74.34 | 2020 | |
| Aerie Pharmaceuticals, INC. | $24.87 | 2019 | |
| Allergan, INC. | $15.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Bark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.